Viemed schedules October 20 presentation. Barrington target for Viemed stock is USD 14.00

Published on 10/18/2026 at 12:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viemed presents at LD Micro on October 20. Second-quarter results for Viemed stock included USD 78.10 million revenue and USD 0.07 diluted EPS.

Viemed dates its investor presentation

Viemed announced its October 20, 2026 presentation on October 6, 2026.
Second-quarter revenue reached USD 78.10 million versus USD 78.00 million consensus.
Barrington Research set a USD 14.00 target on August 24, 2026.
MarketBeat lists November 4, 2026 as the estimated next earnings date.

VMD, CA92663R1055, Illustration mit AI erstellt.

Viemed Healthcare (ISIN CA92663R1055) is scheduled to present at the LD Micro Main Event on October 20, 2026, while Barrington Research has set a USD 14.00 target for the stock. The presentation was announced on October 6, 2026, and the target was reported on August 24, 2026.

The upcoming appearance gives investors a fresh date for management commentary after the company reported second-quarter revenue of USD 78.10 million and diluted earnings per share of USD 0.07. The figures place growth and profitability at the center of the next investor discussion.

Why October 20 matters

According to Yahoo Finance on October 6, 2026, Viemed will present at 12:30 p.m. PT during the October 19-21, 2026 event. Casey Hoyt and members of management are scheduled to represent the company.

The chronology shows how the investor narrative has developed. On August 3, 2026, Viemed reported second-quarter revenue of USD 78.10 million and diluted earnings per share of USD 0.07; on September 24, 2026, a filing disclosed a trading plan covering up to 246,000 shares; on October 6, 2026, the company announced its October 20 presentation. The three dates move from operating results to capital-market communication.

What Q2 results show

MarketBeat reported that second-quarter revenue of USD 78.10 million exceeded USD 78.00 million consensus, while diluted earnings per share of USD 0.07 missed the USD 0.12 estimate by USD 0.05. That split makes margin execution more important than revenue growth alone.

MarketWatch reported the September 24, 2026 filing that disclosed a plan allowing sales of up to 246,000 shares beginning no earlier than December 24, 2026. The filing adds a capital-markets consideration to the operating discussion.

Dates and valuation for investors

The next two dated events are the October 20, 2026 LD Micro presentation and the estimated November 4, 2026 earnings date listed by MarketBeat. Barrington Research initiated coverage on August 24, 2026 with an Outperform rating and a USD 14.00 target, according to the same report.

MarketBeat listed a 52-week range of USD 6.05 to USD 12.61 and a market capitalization of USD 361.1 million as of October 16, 2026. The company describes its business as home-based respiratory care and post-acute healthcare services, with revenue growth needing to translate into stronger earnings conversion.

Stock and upcoming dates

Viemed closed at USD 9.48 on Nasdaq on October 16, 2026. The next scheduled investor presentation is October 20, 2026, followed by the estimated earnings date of November 4, 2026.

The further course of trading is shown by the continuously updated real-time quote of Viemed Healthcare stock.